Although The Wall Street Journal estimated that there was a global market worth US $ 1 billion for Myozyme, Chen believes that in the short term such a market scale is unlikely. That is because "a vast majority of affected children have already died."
雖然美國華爾街日報推估 Myozyme 具有 10 億美元的全球市場規模，但陳垣崇認為短期內不太可能，因為「絕大部分的病童都已經過世」。